Sanofi's Tzield Receives FDA Approval for Diabetes Treatment
By Connor Hart
Sanofi secured accelerated approval from the Food and Drug Administration for its drug Tzield to be used in the treatment of people with the autoimmune and progressive nature of stage 3 type 1 diabetes
The company said Friday that the therapy can delay the decline in endogenous insulin production in children between the ages of eight and 17, who have recently been diagnosed with stage 3 type 1 diabetes.
"Approximately 64,000 people are diagnosed with T1D every year," said Aaron Kowalski, chief executive of Breakthrough T1D. "We are excited that the approval of Tzield in this indication provides a treatment option for certain patients diagnosed in stage 3 T1D, which is when many start experiencing common symptoms of the disease."
Sanofi said the treatment has previously received approvals in the U.K., European Union, China, Australia, Canada, Israel, Saudi Arabia, the United Arab Emirates, Kuwait, Brazil and Switzerland.
Regulatory reviews are ongoing in other jurisdictions around the world, it added.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
June 12, 2026 18:56 ET (22:56 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States